Small Cell Lung Cancer

The AJMC® Lung Cancer compendium is a comprehensive resource for clinical news and expert insights for the condition.

Latest News

Radiotherapy can work synergistically with immunotherapy by reprogramming the tumor microenvironment. | Image credit: Crystallight-stock.adobe.com
Brain Radiotherapy Plus ICIs Boost Survival in SCLC With Brain Metastases

July 30th 2025

A retrospective analysis found whole brain radiation therapy alongside immune checkpoint inhibitors led to “brilliant” 2-year overall survival rates.

As SCLC continues to pose a therapeutic challenge due to rapid progression and early metastasis, the convergence of immunotherapy and precision radiation holds promise to extend survival and improve outcomes. | Image credit: mi_viri - stock.adobe.com
Chemoimmunotherapy Shows Promise for Limited-Stage SCLC in Real-World Study

July 29th 2025

The findings suggest that inhibition of midkine might be a meaningful tool to improve treatment outcomes in SCLC. | Image credit: Pixel-Shot - stock.adobe.com
Midkine May Play Key Role in SCLC

July 24th 2025

Emerging therapies, including immune checkpoint inhibitors and antibody-drug conjugates, could significantly impact SCLC treatment, authors of a recent review concluded. | Image credit: Vitalii Vodolazskyi - stock.adobe.com
Is a New Era of SCLC, LCNEC Treatments on the Horizon?

July 23rd 2025

The investigators found that patients with SCLC and cachexia were more likely to have problems with treatment. | Image credit: appledesign - stock.adobe.com
Cachexia Worsens Prognosis in Older Patients With Advanced SCLC

July 9th 2025

Multidisciplinary Approaches to Paraneoplastic LEMS

Hear from medical experts as they explore the connection between Lambert-Eaton myasthenic syndrome and small cell lung cancer, discussing diagnostic challenges, economic impacts, and strategies for optimizing care.

Hear from medical experts as they explore the connection between Lambert-Eaton myasthenic syndrome and small cell lung cancer, discussing diagnostic challenges, economic impacts, and strategies for optimizing care.
Continuing Medical Education
View All
August 26th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
August 26th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

Dr Davey Daniel Talks Approval of Cemiplimab With Chemotherapy for First-line NSCLC
December 21st 2022

Dr Davey Daniel Talks Approval of Cemiplimab With Chemotherapy for First-line NSCLC

Mary Caffrey Hayden E. Klein
Cemiplimab with chemotherapy appears to offer value comparable to other options and may be "an important tool to use" in first-line treatment of non-small cell lung cancer (NSCLC), said Davey Daniel, MD, chief medical officer for OneOncology, lung cancer specialist.
Hilary Tindle, MD, MPH, Associate Professor of Medicine, Vanderbilt University
December 20th 2022

Dr Hilary Tindle: Tobacco Nation's High Rates of Lung Cancer

Pearl Steinzor
Hilary Tindle, MD, MPH, associate professor of medicine, Vanderbilt University, spoke on increased rates of smoking and lung cancer within a particular region of the United States called "Tobacco Nation."
graphic indicating genetic code
December 9th 2022

Switch to NGS Would Lead to More Targeted NSCLC Care, but May Not Lower Costs

Jared Kaltwasser
The study, based on care in Japan, found patients would be more quickly referred for targeted therapy.
picture of cannabis
December 7th 2022

Cannabis Used With ICIs Appears to Have No Impact on NSCLC Outcomes

Jared Kaltwasser
Differences in overall survival between cannabis users and those who did not use the plant were small and could be explained by differences in the make-ups of the 2 cohorts of patients with non-small cell lung cancer, researchers said.
Image of lung cancer
November 29th 2022

Afatinib Outperforms First-Generation EGFR-TKIs in NSCLC With Uncommon EGFR Mutations

Jared Kaltwasser
The study offers guidance to clinicians treating the roughly 10% of patients with rare EGFR mutations.
Lungs and stethoscope
November 22nd 2022

Early Lung Cancer Screening Program Dramatically Increases Survival Rates

Pearl Steinzor
A recent study stresses the importance of routine CT screening for improving lung cancer survival outcomes.
Lungs
November 16th 2022

Despite Improvements in Lung Cancer Screening, Increased Efforts Still Needed to Address Disparities

Justina Petrullo
The State of Lung Cancer 2022 report issued by the American Lung Association illustrates aspects of diagnosis and care that require additional attention to address disparities and increase nationwide screening and treatment engagement while reducing risk factor exposure.
image of research
November 13th 2022

Doubling Women’s Lung Cancer Research Funding Would Generate Major Returns, Study Says

Jared Kaltwasser
Lung cancer is the number one cause of cancer-related deaths among women in the United States, yet relatively little research funding is spent on the issue, the authors of a new study say.
FDA approved cemiplimab plus chemotherapy for NSCLC
November 9th 2022

FDA Approves Cemiplimab Plus Chemotherapy as First-line NSCLC Treatment

Allison Inserro
The FDA approved cemiplimab (Libtayo) in combination with platinum-based chemotherapy for the first-line treatment of advanced non–small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations.
In Advanced NSCLC, Forgoing Treatment Leads to Increased Health Care Utilization
November 6th 2022

In Advanced NSCLC, Forgoing Treatment Leads to Increased Health Care Utilization

Jared Kaltwasser
A new report underscores how treatment decisions for non-small cell lung cancer (NSCLC) affect patients’ health care utilization and costs.
Image of lung cancer
October 26th 2022

Meta-Analysis Supports Immune Checkpoint Inhibitors in Frontline NSCLC Treatment

Rose McNulty
Immune checkpoint inhibitors, either alone or in combination with chemotherapy, were associated with better outcomes in non–oncogene-addicted non–small cell lung cancer (NSCLC).
Emphasizing Biomarker-Driven Treatment and Individualized Care Strategies for Patients With NSCLC
October 21st 2022

Emphasizing Biomarker-Driven Treatment and Individualized Care Strategies for Patients With NSCLC

Dr Millie Das, MD discusses updates from the 2022 World Conference on Lung Cancer regarding non-small cell lung cancer (NSCLC).
JAVELIN Lung 100 Trial Evaluating Progression-Free and Overall Survival for Patients With NSCLC
October 14th 2022

JAVELIN Lung 100 Trial Evaluating Progression-Free and Overall Survival for Patients With NSCLC

Millie Das, MD, outlines the JAVELIN Lung 100 trial and shares insights on strategies and data interpretation from the trial.
Immunotherapy graphic
October 9th 2022

Immunotherapy in SCC Still Marred by Challenges, Despite Efficacy in Some Patients

Jared Kaltwasser
Among the challenges are a lack of reliable biomarkers and resistance in some patients who have squamous cell carcinoma (SCC).
HUDSON Trial Overview and Key Takeaways
October 7th 2022

HUDSON Trial Overview and Key Takeaways

The HUDSON trial is explored by Dr Das as she provides an overview of the study and offers key considerations regarding results.
Ticiana Leal, MD, Emory University School of Medicine
October 7th 2022

Dr Ticiana Leal: A Lot of Work Is Needed Regarding Early Detection in Lung Cancer

Laura Joszt, MA Skylar Jeremias
Lung cancer screening rates remain low nationwide, and there is a need to better educate patients and clinicians about the importance of screening, said Ticiana Leal, MD, associate professor, director of the Thoracic Medical Oncology Program, Department of Hematology and Medical Oncology, Emory University School of Medicine.
Person walking on a country road
October 6th 2022

NSCLC Differs Between Rural, Urban Patients in Key Ways

Jared Kaltwasser
Molecular differences may help explain geographic gaps in outcomes.
graphic of lung x ray
October 3rd 2022

Most Patients in China With Lung Cancer Experience Financial Toxicity

Jared Kaltwasser
A new report finds despite reforms to the country’s health care system, many patients in China with lung cancer experience stress, and sometimes health consequences, on account of the disease’s financial burden.
Doctor preparing cancer treatments
October 1st 2022

Cemiplimab Shows Improved PFS, Comparable OS to Pembrolizumab in NSCLC

Jaime Rosenberg
In the absence of a head-to-head trial, the researchers compiled data from randomized controlled trials of the 2 PD-1/PD-L1 inhibitors in patients with advanced disease and PD-L1 ≥ 50%.
Aligning Cost-Effective Payer Strategies With Clinical Pathway Considerations for NSCLC Treatment
September 30th 2022

Aligning Cost-Effective Payer Strategies With Clinical Pathway Considerations for NSCLC Treatment

Millie Das, MD, shares key takeaways from her presentation regarding cost-effective strategies and payer considerations related to the treatment of NSCLC.
Ticiana Leal, MD, Emory University School of Medicine
September 29th 2022

Expensive Targeted Lung Cancer Therapies Need to Be Tailored to the Right Patient

Laura Joszt, MA Skylar Jeremias
Targeted therapies have improved outcomes for patients with lung cancer, but the goal needs to be tailoring the right therapy to the right patient, said Ticiana Leal, MD, associate professor, director of the Thoracic Medical Oncology Program, Department of Hematology and Medical Oncology, Emory University School of Medicine.
Hatim Husain, MD, associate professor, Department of Medicine, UC San Diego
September 23rd 2022

Dr Hatim Husain Discusses HER2, Novel Therapy Exploration in Lung Cancer

Hayden E. Klein Maggie L. Shaw
During the Quality Cancer Care Alliance Summer 2022 National Leadership Summit, Hatim Husain, MD, discusses how HER2 exploration in lung cancer differs from that in breast cancer, as well as novel therapies being explored for HER2 and other disease targets.
Evolving NSCLC Treatment Landscape Following IMpower010 Trial Data
September 23rd 2022

Evolving NSCLC Treatment Landscape Following IMpower010 Trial Data

IMpower010 trial data may influence a significant evolution in treatment of non–small cell lung cancer.
Picture of cancer researchers
September 21st 2022

Phase 3 Trial Backs First-line Use of Cemiplimab With Chemotherapy in aNSCLC

Jaime Rosenberg
With these new findings coming from the EMPOWER-Lung 3 trial, the anti-programmed cell death-1 inhibitor cemiplimab is now just the second of its kind to show efficacy in these patients as both monotherapy and as a combination regimen, regardless of histology.
Ticiana Leal, MD, Emory University School of Medicine
September 14th 2022

Real-world Lung Cancer Testing Rates Are Lower Than They Should Be, Says Dr Ticiana Leal

Laura Joszt, MA Skylar Jeremias
Biomarker testing should be done on all patients with an initial diagnosis of advanced nonsquamous non–small cell lung cancer, but the testing rates in the real world are lower than they should be, particularly for underserved or minority populations, said Ticiana Leal, MD, associate professor, director of the Thoracic Medical Oncology Program, Department of Hematology and Medical Oncology, Emory University School of Medicine.
lung cancer
September 12th 2022

Lung Cancer Screening Leads to Earlier Diagnosis, but Not Overdiagnosis

Jared Kaltwasser
A study carried out at 4 health care systems found rates of stage I lung cancer increased, and rates of stage IV cancer decreased, once screening was initiated.
Hatim Husain, MD, associate professor, Department of Medicine, UC San Diego
September 10th 2022

Dr Hatim Husain: NCCN Guidelines Adjust to Meet Lung Cancer Treatment Needs

Maggie L. Shaw Hayden E. Klein
Hatim Husain, MD, discusses how National Comprehensive Cancer Network (NCCN) treatment guidelines adjust to meet the treatment needs of patients with lung cancer.
picture of patient consulting provider
September 8th 2022

Recommendations to Safeguard Quality Shared Decision-Making for Lung Cancer Screening

Allison Inserro
An updated national coverage determination from CMS about lung cancer screening has some stakeholders concerned that the quality of decision-making tools used by providers and patients may weaken.
Hatim Husain, MD, associate professor, Department of Medicine, UC San Diego
August 29th 2022

Dr Hatim Husain: Biomarker Testing Is a Treatment Cornerstone in NSCLC

Hayden E. Klein Maggie L. Shaw
Hatim Husain, MD, associate professor in the Department of Medicine at UC San Diego, discuses must-haves for successful biomarker testing in lung cancer—in particular, non–small cell lung cancer (NSCLC)—and how the field is adapting to the targeted treatment needs of its patients.
Colorful lung graphic
August 23rd 2022

Clinicians Slow to Adopt PD-1, PD-L1 Inhibitors in NSCLC

Jared Kaltwasser
A significant subset of patients continues to receive chemotherapy monotherapy despite the availability of newer approaches, including programmed cell death protein-1 (PD-1) and programmed death ligand-1 (PD-L1) inhibitors.
<12345678910>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo